New technology may be applicable to other autoimmune diseases and allergies
Results of a new phase 2 clinical trial using technology developed at Northwestern Medicine show it is possible to induce immune tolerance to gluten in individuals with celiac disease. The findings may pave the way for treated celiac patients to eventually tolerate gluten in their diet.
After treatment with the technology, the patients were able to eat gluten with a substantial reduction in inflammation. The results also show a trend toward protecting patients’ small intestine from gluten exposure.
The findings will be presented as a late-breaking presentation Oct. 22 at the European Gastroenterology Week conference in Barcelona, Spain.
The technology is a biodegradable nanoparticle containing gluten that teaches the immune system the antigen (allergen) is safe. Thenanoparticle acts like a Trojan horse, hiding the allergen in a friendly shell, to convince the immune system not to attack it.
Beyond celiac disease, the finding sets the stage for the technology — a nanoparticle containing the antigen triggering the allergy or autoimmune disease — to treat a host of other diseases and allergies including multiple sclerosis, type 1 diabetes, peanut allergy, asthma and more.
The technology was developed in the lab of Stephen Miller, professor of microbiology and immunology at Northwestern University Feinberg School of Medicine, who has spent decades refining the technology.
“This is the first demonstration the technology works in patients,” said Miller, the Judy Gugenheim Research Professor of Microbiology and Immunology.“We have also shown that we can encapsulate myelin into the nanoparticle to induce tolerance to that substance in multiple sclerosis models, or put a protein from pancreatic beta cells to induce tolerance to insulin in type 1 diabetes models.”
When the allergen-loaded nanoparticle is injected into the bloodstream, the immune system isn’t concerned with it, because it sees the particle as innocuous debris. Then the nanoparticle and its hidden cargo are consumed by a macrophage, essentially a vacuum-cleaner cell that clears cellular debris and pathogens from the body.
“The vacuum-cleaner cell presents the allergen or antigen to the immune system in a way that says, ‘No worries, this belongs here,’” Miller said. “The immune system then shuts down its attack on the allergen, and the immune system is reset to normal.”
In the celiac disease trial, the nanoparticle was loaded with gliadin, the major component of dietary gluten, found in cereal grains such as wheat. A week after treatment, the patients were fed gluten for 14 days. Without treatment, celiac patients eating gluten developed marked immune responses to gliadin and damage in their small intestine. Celiac patients treated with the COUR nanoparticle, CNP-101, showed 90% less immune inflammation response than untreated patients. By stopping the inflammatory response, CNP-101 showed the capacity to protect the intestines from gluten related injury.
There currently is no treatment for celiac disease.
“Doctors can only prescribe gluten avoidance, which is not always effective and carries a heavy social and economic toll for celiac patients,” Miller said.
About 1% of the population has celiac disease,a serious autoimmune disease in which the ingestion of gluten leads to damage in the small intestine. When people with celiac disease eat gluten (a protein found in wheat), their body mounts an immune response that attacks the small intestine.
Autoimmune diseases generally can only be treated with immune suppressants that provide some relief, but undermine the immune system and lead to toxic side-effects. CNP-101 does not suppress the immune system but reverses the course of disease.
“Celiac disease is unlike many other autoimmune disorders because the offending antigen (environmental trigger) is well known — gluten in the diet,” said Dr. Ciaran Kelly, professor of medicine at Harvard Medical School and director of the Celiac Center at Beth Israel Deaconess Medical Center. “This makes celiac disease a perfect condition to address using this exciting nanoparticle induced immune tolerance approach.”
Kelly, who will be presenting the research abstract in Barcelona, has been working with Miller to apply the technology and define the therapeutic approach to treating celiac disease.
The nanotechnology was licensed to COUR Pharmaceuticals Co., a biotech based in Northbrook and co-founded by Miller. COUR developed CNP-101, which was granted Fast Track status from the U.S. Food and Drug Administration, and brought the therapy to patients in collaboration with Takeda Pharmaceuticals. Takeda will announce Tuesday they have acquired an exclusive global license to develop and commercialize this investigational medicine for celiac disease.
“Given the license by Takeda, COUR will focus on clinical programs in peanut allergy and multiple sclerosis in the near term and broaden even further over time,” said John J. Puisis, president and chief executive officer of COUR.
Learn more: New treatment may reverse celiac disease
The Latest on: Celiac disease
[google_news title=”” keyword=”celiac disease” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Celiac disease
- 10 signs you might have celiac disease or gluten sensitivityon May 8, 2024 at 7:12 am
Ever heard of celiac disease or gluten sensitivity and wondered, “Could that be me?” Early detection and diagnosis can be game-changers. In this article, learn the top 10 signs that you might have ...
- 22 foods and drinks you didn’t know contain glutenon May 8, 2024 at 1:23 am
But there are also some surprising sources of gluten out there, so if you have Celiac disease or gluten sensitivity — or you’re preparing a meal for someone who fits this description — you’ll want to ...
- Celiac Cruise adds more gluten-free river trips with AmaWaterwayson May 7, 2024 at 5:40 pm
The collaboration has already delivered cruises with 100% gluten-free vessels and experiences on the Danube and Seine. Celiac Cruise has now become AmaWaterways' exclusive partner for all gluten-free ...
- Jena DeMoss: Dietitian’s guide to gluten-freeon May 7, 2024 at 3:39 pm
You may have heard of gluten-free diets, but do you know if you need to follow them or what a gluten-free diet entails? As Hy-Vee registered dietitians, we help our clients navigate their dietary ...
- The Spectrum of Celiac Disease: Epidemiology, Clinical Aspects and Treatmenton May 5, 2024 at 5:00 pm
Celiac disease is a gluten-sensitive enteropathy that affects people of all ages worldwide. This disease has emerged as a major health-care problem, as advances in diagnostic and screening methods ...
- Understanding celiac diseaseon May 2, 2024 at 9:29 pm
But do you know that the ingestion of gluten protein, present in certain foods, can lead to celiac disease? Although the exact root cause is unknown, the consequence may necessitate a lifelong ...
- Top 6 Best Iron Supplement for Celiac Disease in 2024on April 25, 2024 at 5:00 pm
Nevertheless, people with celiac disease often battle with iron deficiency anemia, a condition that arises from the damage inflicted on their small intestine, thereby hampering the body’s ...
- Three Gluten-Free Friendly Restaurantson April 25, 2024 at 1:00 pm
And by far, the query that has appeared in my inbox with the greatest frequency has been about gluten-free dining. More than 2 million Americans have been diagnosed with Celiac — though researchers ...
- First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrientson April 24, 2024 at 6:00 am
The featured paper is entitled “Dynamics of Serologic Change to Gluten in Celiac Disease Patients” (doi.org/10.3390/nu15245083). The manuscript benefits from one of the largest databases of CeD ...
- What’s the Connection Between Celiac Disease and Obesity?on April 9, 2024 at 5:00 pm
You can have obesity and receive a diagnosis of celiac disease. If you have a moderate weight at diagnosis, it’s possible to gain weight on a gluten-free diet. Celiac disease is an abnormal ...
via Bing News